Sorafenib plus doxorubicin in advanced hepatocellular carcinoma patients: hope or hype? [PDF]
, 2020 Kit Shing +4 more
openalex +1 more source
Supplementary Figure 4 from Regulation of CD4<sup>+</sup>NKG2D<sup>+</sup> Th1 Cells in Patients with Metastatic Melanoma Treated with Sorafenib: Role of IL-15Rα and NKG2D Triggering [PDF]
, 2023 Ana I. Romero +21 more
openalex +1 more source
Head &Neck, EarlyView.ABSTRACT Background Brain metastases (BM) of differentiated thyroid carcinoma (DTC) are associated with unfavorable prognosis. This study evaluated BM management strategies and patients' outcomes. Methods A retrospective review of patients diagnosed with DTC and BM at Tel Aviv Sourasky and Rabin Medical Centers between 1985 and 2024. Clinical features,
Liyona Kampel +9 more
wiley +1 more source
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. [PDF]
, 2017 BackgroundInternal tandem duplication mutations in FLT3 are common in acute myeloid leukaemia and are associated with rapid relapse and short overall survival.
Altman, Jessica K +25 more
core +1 more source
The inhibition of FGF receptor 1 activity mediates sorafenib-induced antiproliferative effects in human mesothelioma tumor-initiating cells [PDF]
, 2017 Tumor-initiating cells (TICs), the subset of cells within tumors endowed with stem-like features, being highly resistant to conventional cytotoxic drugs, are the major cause of tumor relapse.
A Bajetto +63 more
core +2 more sources
RNA Vaccine: novel approach for cancer treatment [PDF]
, 2011 Cancer is still an unsolved puzzle and a major cause of mortality and morbidity in the world. Today, about one in every thousand people is dying due to cancer. No effective agent has yet been found which can cure cancer in its metastatic stage.
Kanika Bhalla +2 more
core +2 more sources
International Journal of Cancer, EarlyView.What's New? Most patients with ovarian cancer (OC) relapse after first‐line chemotherapy, and prognosis with second‐line treatment depends largely on the platinum‐free interval. However, reliable biomarkers to predict response to second‐line therapy remain lacking.
Muhammad Habiburrahman +7 more
wiley +1 more source
Global patterns and trends in kidney cancer incidence and mortality
International Journal of Cancer, EarlyView.What's New? Decreasing mortality from kidney cancer in developed countries contrasts with persistently high or rising mortality in less‐developed regions. Factors underlying this widening gap remain incompletely understood. Using GLOBOCAN 2022 data, the present study examined patterns in kidney cancer incidence and mortality worldwide and the relation ...
Anton Barchuk +5 more
wiley +1 more source
Multidisciplinary Management of Patients with Unresectable Hepatocellular Carcinoma: A Critical Appraisal of Current Evidence [PDF]
, 2019 Hepatocellular carcinoma (HCC) is a leading cause of new cancer diagnoses in the United States, with an incidence that is expected to rise. The etiology of HCC is varied and can lead to differences between patients in terms of presentation and natural ...
Gholam, Pierre M. +2 more
core +1 more source